BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Bargains & Bubbles

Nike at $39: The Price That Doesn’t Match the Brand, or the Math

Moe Alsumidaie, MBA, MSF by Moe Alsumidaie, MBA, MSF
August 18, 2026
in Bargains & Bubbles
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

Five years ago, Nike was the envy of every consumer brand on earth. Revenue was climbing, the stock was north of $170, and the company had convinced itself it could sell directly to consumers and cut out the retailers it had spent decades building. That bet went badly. By the time Nike reversed course, it had lost shelf space, alienated wholesale partners, and watched a generation of challengers fill the gap. Today the stock trades near its lowest point in twelve years, and the question sitting in the middle of every conversation about this company is a simple one: has the price fallen far enough to reflect all of that damage, or has it fallen too far?

In one breath

Nike’s filed numbers show a business that shrank by nearly a tenth last fiscal year and is barely growing now, with margins at their lowest in a decade. The stock, at $39, is priced at a multiple the company has only seen in its cheapest sliver of trading days over the past ten years. Those two readings sit in genuine tension: the math says the mood has turned very dark, but the mood may have good reasons that the math alone can’t settle.

How the swoosh got here

The turning point has a precise date. In September 2021, factory shutdowns in Vietnam forced Nike to miss its own revenue forecast and cut its outlook for the year. That was the first crack. Management’s response, doubling down on selling directly through Nike’s own app and stores while pulling back from retailers like Foot Locker, looked smart on paper. It was not. Wholesale partners filled their shelves with Hoka, On, and New Balance instead. Nike’s lifestyle franchises, the Air Force 1s and Dunks that had carried the brand through the pandemic, went cold from overexposure. By the fiscal year ended May 2025, revenue had fallen nearly 10% and net income had dropped by nearly half.

The reversal is now underway. Nike brought back a new CEO, rebuilt wholesale relationships, and launched what it calls a “Sport-First” strategy, putting performance product back at the center. A round of restructuring, including roughly 1,400 technology job cuts announced in April 2026, generated about $300 million in charges. New regional leaders arrived in EMEA and Greater China. The machinery of a turnaround is visible. Whether it is working is a different question.

BullScope TerminalWant the full evidence sheet behind pieces like this?The terminal runs the complete workup: Nike and 500+ other names, on the same official data.See the evidence engine →

What the fiscal 2026 filing actually shows

The 10-K for the fiscal year ended May 31, 2026 tells a story of stabilization that is real but fragile. Revenue came in at $46.4 billion, essentially flat with the prior year. That flatness is better than the steep decline that preceded it, but it is not growth. The gross margin, which measures what is left of each dollar of sales after the cost of making and shipping the shoe, edged up slightly to 42.9%. Operating income rose modestly year over year.

Here is where the story gets complicated. The fourth quarter’s headline gross margin looks extraordinary, but Nike’s own earnings release explains why: a nearly $1 billion one-time recovery of tariffs collected under the IEEPA trade rules added roughly 900 basis points to that quarter’s margin. Strip that out and the underlying margin was below where it stood a year ago. A one-time windfall is not a trend, and a reader deciding what this business normally earns should set it aside.

Free cash flow, the actual dollars the business generated after capital spending, fell by a third to $2.2 billion. That is still real money, enough to nearly cover what Nike returned to shareholders through dividends and buybacks, but only just. The cushion is thinner than it looks.

The China problem has no easy answer

Walk into a Nike store in Shanghai today and the shelves are full. The problem is that fewer people are walking in. Greater China revenue fell sharply for the full fiscal year 2026, and Nike’s own digital sales in the region dropped by more than a quarter. This is not a tariff problem or a currency problem. It is a brand problem in a market where local competitors have gained real ground. Management installed a new regional leader, Cathy Sparks, in March 2026, and the “Sport-First” pivot is meant to resonate with Chinese consumers who are buying performance gear for running and fitness. Whether a brand rebuilt on American sport culture can reclaim that ground is the open question the filing cannot answer.

The mood versus the math

Our data, computed from SEC filings and current market prices, shows Nike trading at a price-to-earnings multiple of 11 times, sitting in the cheapest 8% of its own decade of valuations. In plain terms: the market is paying less for each dollar of Nike’s sales than it has at almost any point in recent memory.

BullScope TerminalYou just read Nike’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →

That is the math. The mood is darker still. In August 2026, JP Morgan’s Matthew Boss downgraded Nike to “Underweight”, cutting his valuation estimate to $40 and arguing that the “Win Now” strategy could weigh on future profitability. The stock hit a fresh 52-week low shortly after, its weakest close in roughly a decade. Morningstar, by contrast, published a fair value estimate more than double the current price on July 22, 2026, citing brand strength and long-term turnaround potential. The gap between those two named, credentialed analysts looking at the same company is itself the story: nobody agrees on what this business is worth right now, because nobody agrees on whether the turnaround is real.

What the balance sheet says about staying power

One thing the filing settles clearly is that Nike is not in financial distress. Cash on hand stood at $9 billion against total debt of roughly $11 billion, leaving a net debt position smaller than a single year of free cash flow. A company in genuine trouble cannot return billions to shareholders while funding a global restructuring. The balance sheet buys time. It does not, by itself, fix China or rebuild digital sales.

Reading the numbers

  • Revenue, FY2026: $46.4 billion, flat year-over-year. What it is: total sales across every Nike product and geography. What it means here: after a nearly 10% decline in FY2025, flat is stabilization, not recovery. In everyday terms: imagine a shop that lost one shelf in ten last year, then stopped losing shelves this year. The shelf is still gone; it just stopped shrinking.
  • Gross margin, FY2026: 42.9%, up 20 basis points. What it is: of every dollar Nike collects from a sale, 43 cents remain after paying for the product and getting it to market. What it means here: the improvement is real but thin, and the Q4 headline of 49.2% included a nearly $1 billion one-time tariff refund that will not repeat. A household analogy: if a landlord’s rental income looks higher this year only because a tenant repaid a deposit, next year’s income will look lower again.
  • Free cash flow, FY2026: $2.2 billion, down 33% from FY2025. What it is: cash the business actually generated after all spending, the number that funds dividends and buybacks. What it means here: Nike returned more to shareholders than it generated in free cash flow, which is sustainable only briefly. A family spending $2,500 a month while earning $2,200 can do it for a while if savings are deep; Nike’s $9 billion cash pile is that savings account.
  • P/E ratio, current: 11 times, versus a ten-year median of 16 times. What it is: the price tag per dollar of annual profit. A multiple of 11 means the market pays $11 for every $1 Nike earns. What it means here: at the decade median, the same earnings would support a price roughly 45% higher. That gap is not a forecast; it is a description of how far sentiment has moved from historical norms.

Sources

  • Nike 10-K, fiscal year ended May 31, 2026 (SEC EDGAR)
  • Nike 10-K, fiscal year ended May 31, 2025 (SEC EDGAR)
  • Nike FY2026 Q4 and Full Year Earnings Release
  • 247 Wall St.: Nike falls to fresh 52-week low, August 17, 2026
  • MarketBeat: Nike analyst forecasts and valuation estimates
  • MarketBeat: Nike hits new 12-month low, August 17, 2026
  • SGB Online: Nike restructuring charges and layoffs
  • CompaniesMarketCap: Nike cash on hand
  • CompaniesMarketCap: Nike total debt
  • Huddle Up: Nike global supply chain challenges
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read Nike’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie, MBA, MSF

Moe Alsumidaie, MBA, MSF

Moe Alsumidaie, MBA, MSF is the Chief Editor of BullScope. Trained in finance, with a Master of Science in Finance and an MBA, he spent years inside large public healthcare companies including Abbott, Genentech, and Roche, learning how the businesses behind the filings actually run. As a journalist and Chief Editor of The Clinical Trial Vanguard, his reporting has appeared in Applied Clinical Trials, The American Journal of Managed Care, and CNET, and has been cited in U.S. Supreme Court proceedings. At BullScope he brings those disciplines together: every note starts in the SEC filings, runs through published methodology, and shows its work.

Recommended For You

Halozyme: The Royalty Machine Trading at a Premium to Its Own History

by Moe Alsumidaie, MBA, MSF
September 9, 2026
0

Six years ago, Halozyme Therapeutics was a mid-sized biotech with a clever idea and a thin income statement. The idea was ENHANZE, a drug-delivery technology that dissolves the...

Read moreDetails

Merck Is Printing Money and Losing Money at the Same Time. Both Are True.

by Moe Alsumidaie, MBA, MSF
September 7, 2026
0

A trailing price-to-earnings ratio of 120 sits next to a price-to-sales ratio near its highest point in a decade. Those two numbers describe the same stock on the...

Read moreDetails

A $2.4 Billion Question: What Sarepta’s Filed Numbers Actually Say

by Moe Alsumidaie, MBA, MSF
September 3, 2026
0

The gist of it Sarepta's filed numbers tell a story of a company that briefly turned profitable in 2024, then swung back to a loss in 2025 after...

Read moreDetails

The Quiet Compounder at a Loud Price: What Royalty Pharma’s Filings Actually Say

by Moe Alsumidaie, MBA, MSF
September 2, 2026
0

Royalty Pharma's stock sat at an all-time low in December 2024. By late August 2026, it had touched an all-time high above $62. That is a gain of...

Read moreDetails

Half the Price, Same Business: What Zoetis’s Filed Numbers Actually Say

by Moe Alsumidaie, MBA, MSF
August 31, 2026
0

Two years ago, Zoetis traded at roughly 35 times its annual earnings. Today it trades at roughly 12 times. The revenue line has kept growing. The margin line...

Read moreDetails
Next Post

Lowe's: The Stock Is Down a Quarter, the Business Just Grew 10%. The Gap Is the Story.

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Gilead’s Books Say One Thing. The Price Tag Says Another. Here’s What the Filings Actually Show.

August 20, 2026

AbbVie Reaffirms 2026 Guidance After Closing $10.9 Billion Apogee Acquisition

September 4, 2026

Moderna at 28 Times Sales: One Trial Result Is Doing a Lot of Work

September 3, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.